Largest biotech by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Gilead Sciences leads the 24 biotech ranked by net assets, at SGD 29.3B, ahead of BioNTech (SGD 27.5B) and Biogen (SGD 23.5B). Figures as of 18 Nov 2026, 15:14 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Gilead SciencesSGD 29.3B
- Median
- SGD 2.6B
- Combined market value
- SGD 1.09T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | SGD 29.3B | SGD 270.6B | SGD 218.13 | 0.65% down | 33% up | ||
| 2 | BioNTechBNTX · Health Care | SGD 27.5B | SGD 27.2B | SGD 109.58 | 0.14% up | 16% down | ||
| 3 | BiogenBIIB · Health Care | SGD 23.5B | SGD 47.7B | SGD 322.75 | 0.20% down | 49% up | ||
| 4 | AmgenAMGN · Health Care | SGD 11.2B | SGD 314.2B | SGD 580.83 | 1.64% down | 34% up | ||
| 5 | ModernaMRNA · Health Care | SGD 11.2B | SGD 107.7B | SGD 266.06 | 0.23% down | 755% up | ||
| 6 | argenxARGX · Health Care | SGD 9.4B | SGD 77.9B | SGD 1,239.30 | 1.43% up | 4% up | ||
| 7 | QiagenQGEN · Health Care | SGD 4.9B | SGD 13.2B | SGD 64.04 | 0.18% down | 12% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | SGD 4.2B | SGD 21.3B | SGD 210.59 | 1.57% down | 20% up | ||
| 9 | VaxcytePCVX · Health Care | SGD 3.5B | SGD 12.1B | SGD 76.21 | 0.51% down | 22% up | ||
| 10 | ExelixisEXEL · Health Care | SGD 2.8B | SGD 21.8B | SGD 89.18 | 0.96% up | 63% up | ||
| 11 | Bio-TechneTECH · Health Care | SGD 2.7B | SGD 14.7B | SGD 93.75 | 0.10% up | 26% up | ||
| 12 | RepligenRGEN · Health Care | SGD 2.7B | SGD 14.2B | SGD 222.28 | 6.29% up | 5% up | ||
| 13 | CRISPR TherapeuticsCRSP · Health Care | SGD 2.5B | SGD 5.2B | SGD 53.81 | 3.94% up | 21% down | ||
| 14 | Revolution MedicinesRVMD · Health Care | SGD 2.1B | SGD 45.1B | SGD 208.66 | 0.54% down | 131% up | ||
| 15 | Kymera TherapeuticsKYMR · Health Care | SGD 2B | SGD 13.6B | SGD 158.83 | 1.36% up | 87% up | ||
| 16 | Krystal BiotechKRYS · Health Care | SGD 1.6B | SGD 11.8B | SGD 398.97 | 3.63% up | 46% up | ||
| 17 | ImmunovantIMVT · Health Care | SGD 1.1B | SGD 9B | SGD 43.73 | 2.11% up | 43% up | ||
| 18 | CG OncologyCGON · Health Care | SGD 970.5M | SGD 9.1B | SGD 102.26 | 0.46% up | 85% up | ||
| 19 | Twist BioscienceTWST · Health Care | SGD 609.9M | SGD 10.3B | SGD 151.34 | 4.79% up | 340% up | ||
| 20 | Scholar Rock HoldingSRRK · Health Care | SGD 316.6M | SGD 7.6B | SGD 62.48 | 7.48% up | 14% up | ||
| 21 | Adaptive BiotechnologiesADPT · Health Care | SGD 282.1M | SGD 6B | SGD 37.18 | 1.21% up | 88% up | ||
| 22 | Kodiak SciencesKOD · Health Care | SGD 202.9M | SGD 8.4B | SGD 127.93 | 2.48% up | 396% up | ||
| 23 | Halozyme TherapeuticsHALO · Health Care | SGD 62.9M | SGD 14.3B | SGD 125.31 | 1.26% up | 37% up | ||
| 24 | ImmunityBioIBRX · Health Care | -SGD 645.4M | SGD 9.1B | SGD 8.56 | 6.07% up | 193% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 1.2895 SGD).
Questions and answers
Which biotech rank first by net assets?
Gilead Sciences (SGD 29.3B), BioNTech (SGD 27.5B) and Biogen (SGD 23.5B) are the top three of the 24 biotech ranked by net assets as of 18 Nov 2026, 15:14 UTC.
How many biotech are in this ranking?
24 are ranked by net assets.
What are these biotech worth together?
The 24 biotech ranked by net assets have a combined market value of SGD 1.09T as of 18 Nov 2026, 15:14 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by net assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.